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ABSTRACT
Numerous studies have demonstrated that dietary intervention may promote 
health and help prevent Alzheimer’s disease (AD). We recently reported that bee 
products of royal jelly (RJ) and enzyme-treated royal jelly (eRJ) were potent to 
promote healthy aging in C. elegans. Here, we examined whether RJ/eRJ consumption 
may benefit to mitigate the AD symptom in the disease model of C. elegans. Our results 
showed that RJ/eRJ supplementation significantly delayed the body paralysis in AD 
worms, suggesting the β-amyloid (Aβ) toxicity attenuation effects of RJ/eRJ. Genetic 
analyses suggested that RJ/eRJ-mediated alleviation of Aβ toxicity in AD worms 
required DAF-16, rather than HSF-1 and SKN-1, in an insulin/IGF signaling dependent 
manner. Moreover, RJ/eRJ modulated the transactivity of DAF-16 and dramatically 
improved the protein solubility in aged worms. Given protein solubility is a hallmark 
of healthy proteostasis, our findings demonstrated that RJ/eRJ supplementation 
improved proteostasis, and this promotion depended on the transactivity of DAF-16. 
Collectively, the present study not only elucidated the possible anti-AD mechanism 
of RJ/eRJ, but also provided evidence from a practical point of view to shed light on 
the extensive correlation of proteostasis and the prevention of neurodegenerative 
disorders.
INTRODUCTION
Alzheimer’s disease (AD) is the most observed 
neurodegenerative disorder in aged populations. Given age 
is the greatest risk factor for AD development, the aging 
of the baby-boom generation will lead to the explosive 
increase in the number of people with AD in the United 
States. As neuropathological lesions gradually impair the 
ability of thinking, communication, and memory [1-4], it 
is a big challenge for medical professionals to take care 
of AD patients. The steep cost of caring for these patients 
will be another significant impact on the healthcare 
system. Therefore, finding means to prevent or delay the 
onset of AD is one of the most urgent commitments in 
aging research. 
A growing body of evidence showed that 
environmental stresses and cellular lesions may cause 
protein misfolding, aggregation, and amyloid formation, 
which are associated with protein toxicity and various 
disorders [5, 6]. Thus, aggregation and accumulation 
of aberrant proteins are shared common features of 
many age-related neurodegenerative diseases, although 
detailed molecular mechanisms of their pathogenesis 
remain unclear [7, 8]. AD is considered a proteotoxicity 
caused disease, which manifests obvious β-amyloid 
(Aβ) aggregations and Tau proteins nucleation [9, 10]. It 
is known that eukaryotic cells equipped a sophisticated 
network (proteostasis network) to maintain healthy 
proteostasis by eliminating aberrant proteins and 
concomitant proteotoxicity [11]. However, aging will 
perturb this regulatory network and decrease the protective 
capacity of proteostasis [12, 13]. Thus, developing 
therapeutic means to promote proteostasis network is a 
promising research avenue for the treatment of AD and 
other neurodegenerative disorders. 
Numerous studies have shown that active 
ingredients from functional foods potently promote 
healthy aging [14-18], implying that dietary intervention 
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may be a feasible means to prevent or delay the onset 
of AD. Royal jelly (RJ) and enzyme-treated RJ (eRJ) 
are consumed as functional foods due to their beneficial 
effects, such as antimicrobial, anti-inflammation, immune-
modulation, and anti-oxidation [19, 20]. RJ is secreted by 
worker bees and used for developing and maintaining 
the queen bees [21]. eRJ is produced by digestion of 
RJ with a hydrolytic enzyme to decrease the allergenic 
properties [22]. We recently reported that supplementation 
of both RJ and eRJ significantly promoted lifespan and 
stress resistance in C. elegans [18]. Given that certain 
nutraceuticals with prolongevity effects may promote 
proteostasis and attenuate proteotoxicity [17], it is 
intriguing to test whether RJ/eRJ is able to influence the 
proteostasis network to prevent or delay AD. 
C. elegans that model age-related disorders of 
neurodegeneration offers tremendous opportunities to 
study the molecular mechanisms of these diseases and to 
determine the effectiveness of therapeutic strategies [23-
27]. To date, studies from worm models demonstrated 
that reduction of insulin/IGF signaling pathway (IIS) 
protected organisms from proteotoxicity [28-34]. 
Remarkably, these findings were reported to be conserved 
in mammalian animals [35-37]. CL2006 is a transgenic 
C. elegans in which human Aβ1-42 is constitutively 
expressed in the muscle cells. The subsequent aggregation 
of Aβ polypeptides leads to progressive body paralysis 
[30, 38], providing a unique platform to study AD and 
proteotoxicity. Here, we supplemented CL2006 worms 
with RJ/eRJ and investigated whether RJ/eRJ may help 
alleviate Aβ toxicity. Our results showed that RJ/eRJ 
dramatically delayed the progression of Aβ toxicity-
induced paralysis and significantly reduced Aβ species 
in AD worms. Further genetic analyses showed that this 
anti-AD effect required DAF-16, rather than HSF-1 and 
SKN-1, in an IIS dependent manner. In addition, we found 
that RJ/eRJ supplementation substantially improved the 
protein solubility in aged worms. Considering that protein 
solubility associates with healthy proteostasis, these results 
demonstrated that RJ/eRJ acts through IIS and DAF-16 to 
promote proteostasis and mitigate proteotoxicity. Taken 
together, our findings not only revealed the possible 
molecular mechanism of RJ/eRJ-mediated protection 
against Aβ toxicity, but also highlighted the regulation of 
DAF-16 on the proteostasis network from a practical point 
of view.
RESULTS
RJ/eRJ supplementation delays the progression of 
paralysis in AD worms
To determine whether RJ/eRJ possesses the 
beneficial effects to AD treatment, CL2006 worms were 
employed and the body paralysis was used as the readout 
to assess the degree of Aβ toxicity. As we previously 
reported that 2mg/ml RJ and 1mg/ml eRJ significantly 
prolonged C. elegans lifespan, the same concentrations 
of RJ and eRJ were adopted in this study [18]. In brief, 
synchronous CL2006 L4/young adult worms were 
treated with or without RJ/eRJ (2mg/mL and 1mg/
mL, respectively) at 20°C and paralyses were measured 
every day until all AD worms were paralyzed. Our data 
indicated that RJ/eRJ supplementation dramatically 
delayed the progression of CL2006 worms’ paralysis when 
compared with the non-supplemented controls (Figure 1). 
Considering that body paralysis is mainly triggered by Aβ 
toxicity, our finding suggested that RJ/eRJ could potently 
alleviate Aβ toxicity in AD worms.
RJ/eRJ supplementation reduces the amount of 
Aβ species in AD worms
It is reported that many nutraceuticals delayed the 
development of AD by mitigating Aβ toxicity through 
decreasing Aβ species [17, 39-41]. We questioned whether 
RJ/eRJ was able to alleviate Aβ toxicity through a similar 
mechanism. To this end, synchronized CL2006 young 
adult worms were treated with or without RJ/eRJ (2mg/
mL and 1mg/mL, respectively) for 10 days at 20°C. 
Afterward, Western blotting was performed to assay 
for the total amount of Aβ species in these 10-day aged 
worms. Data were analyzed using NIH ImageJ software, 
and our findings showed that the total amount Aβ species 
in AD worms treated with RJ and eRJ were 13.61% and 
21.90% less than that in the control AD worms, which 
were statistically significant (p < 0.05, Figure 2). Given 
that the amount of Aβ species contribute to Aβ toxicity, 
Figure 1: Supplementation of both RJ and eRJ mitigates 
Aβ toxicity in C. elegans. The CL2006 worms treated with RJ 
(dashed line) and eRJ (dotted line) showed delayed progression 
of body paralysis as compared to the control worms (solid line). 
Each paralysis assay was conducted in triplicates and repeated 
at least three times with similar results. “% paralysis” indicates 
the average paralysis among the multi-replicates and error bars 
represent the standard deviation.
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our results suggested that RJ/eRJ attenuated Aβ toxicity, at 
least in partial, by reducing the level of Aβ species.
IIS and DAF-16 are required in RJ/eRJ-mediated 
protection against Aβ toxicity
It was reported that the reduction of IIS prevented 
neurodegeneration in mammals and worms by modulating 
the transactivities of its downstream transcription factors 
[42]. Our previous studies showed that IIS and DAF-
16 played an essential role in RJ/eRJ-mediated lifespan 
extension and stress resistance [18]. Considering the 
potential link between prolongevity and anti-AD function, 
we wondered whether IIS and DAF-16 also played an 
imperative role in RJ/eRJ-mediated protection against 
Aβ toxicity. To address this, the paralysis progression of 
CL2006 worms supplemented with RJ/eRJ was monitored 
when the gene expression of daf-2, age-1, and daf-16 were 
individually knocked down via RNA interference (RNAi). 
In detail, synchronous AD worms were collected from 
RJ/eRJ containing NGM plates seeded with particular 
aforementioned RNAi or a paired control (empty vector, 
EV) bacteria. When worms developed into L4/young 
adult, paralysis assays were performed every day until 
all AD worms were paralyzed. In our assays, RJ/eRJ 
supplementation still dramatically delayed the progression 
of paralysis in CL2006 worms treated with paired control 
RNAi. In contrast, RNAi of daf-2, age-1, and daf-16 in 
CL2006 worms completely abolished RJ/eRJ-mediated 
beneficial effects on delaying the progression of paralysis 
(Figure 3A, 3B, and 3C). These findings together 
suggested that IIS and DAF-16 were essential in RJ/eRJ-
mediated protective effect against Aβ toxicity. 
As DAF-16 is a versatile transcription factor, it is 
very likely that the RJ/eRJ-mediated protection against 
Aβ toxicity may depend on the transactivity of DAF-
16. To examine this speculation, synchronized CL2006 
L4/young adult worms were treated with or without RJ/
eRJ for 6 days, and some representative target genes 
of DAF-16 were selected to measure their expression 
levels, individually. Our results showed that sod-3, mtl-
1, Y71H2AR.2, hsp-16.2, and hsp-12.6 were significantly 
upregulated in CL2006 worms treated with RJ/eRJ when 
compared with non-supplemented controls (Figure 3D). 
These results not only indicated that RJ/eRJ protected 
against Aβ toxicity through modulating the transactivities 
of DAF-16, but also further confirmed our genetic 
analysis that daf-16 was required by RJ/eRJ to delay the 
progression of paralysis in AD worms. 
HSF-1 and SKN-1 are dispensable in RJ/eRJ-
mediated protection against Aβ toxicity
In addition to DAF-16, SKN-1 and HSF-1 are two 
other important transcription factors downstream of IIS, 
and also play an important role in alleviating Aβ toxicity 
in C. elegans [42]. Given that RJ/eRJ relied on IIS to 
alleviate Aβ toxicity, we were curious whether SKN-1 
and HSF-1 may also contribute to this RJ/eRJ-mediated 
anti-AD effect, just like DAF-16. To this end, CL2006 
worms supplemented with RJ/eRJ were fed with RNAi 
bacteria of skn-1 and hsf-1, respectively. CL2006 worms 
fed with control RNAi (paired empty vector) bacteria 
served as controls. Intriguingly, our results showed that 
supplementation of RJ/eRJ still delayed the progression 
of paralysis in CL2006 worms fed with skn-1 or hsf-1 
RNAi bacteria (Figure 4A and 4B). These results indicated 
that SKN-1 and HSF-1 might be dispensable in RJ/eRJ-
mediated protection against Aβ toxicity. 
RJ/eRJ supplementation improved proteostasis in 
aged C. elegans
Proteostasis machinery alleviates proteotoxicity 
to maintain the integrity of the proteome [43-47]. Given 
that RJ/eRJ consumption mitigated Aβ toxicity in AD 
worms, we speculated whether RJ/eRJ may modulate 
the proteostasis network to present anti-AD effect in 
aged populations. Thus, we tested the overall solubility 
of proteins in aged worms since protein solubility is a 
primary hallmark of healthy proteostasis [45, 48, 49]. 
Specifically, synchronized worms of wild type N2 and 
CL2006 treated with or without RJ/eRJ were harvested 
to extract total proteins. After sonication and high speed 
centrifugation, soluble fractions were isolated from the 
total proteins. SDS-PAGE and ImageJ were utilized 
Figure 2: Supplementation of both RJ and eRJ reduces 
the amount of total Aβ species. Western blot analysis was 
conducted using 10-day old CL2006 worms. Aβ species are 
quantified by using ImageJ software. A significant reduction of 
intensity is observed in the samples from worms that had been 
treated with RJ and eRJ. The graph shows the mean intensity of 
Aβ species and is the result of three independent experiments. 
p value was calculated using Student’s t-test. *, p < 0.05 when 
compared to controls.
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to determine whether RJ/eRJ affected the solubility of 
proteins in aged C. elegans. Relative to non-supplemented 
controls, RJ/eRJ supplementation increased 26.95% (RJ) 
and 26.87% (eRJ) of soluble proteins in N2 worms (Figure 
5A). Similarly, RJ/eRJ also displayed an average increase 
of 27.13% (RJ) and 21.27% (eRJ) of soluble proteins 
in CL2006 worms as compared to non-supplemented 
controls (Figure 5B). Together, these results suggested 
that RJ/eRJ profoundly improved proteostasis in aged C. 
elegans.
Given the fact that DAF-16 was essential in RJ/
eRJ-mediated lifespan extension, stress resistance, and 
protection against Aβ toxicity, we speculated that DAF-
16 may also participate in RJ/eRJ-mediated promotion of 
proteostasis and protein solubility. To test this speculation, 
synchronized daf-16 (mgDf50) mutant worms were treated 
with or without RJ/eRJ for 10 days. Thereafter, worms 
were collected for total protein extraction. Sonication 
and centrifugation were utilized to remove the insoluble 
proteins, and the amount of soluble proteins was analyzed 
by SDS-PAGE and ImageJ software. Not surprisingly, 
RJ/eRJ-mediated improvement of protein solubility was 
abolished in the daf-16 deletion mutant, suggesting the 
essential role of daf-16 in RJ/eRJ-mediated promotion of 
proteostasis (Figure 5C).
Figure 3: RJ/eRJ requires IIS and DAF-16 to protect against Aβ toxicity in CL2006 worms. A. RJ/eRJ supplementation 
cannot further postpone the progression of body paralysis in CL2006 worms with reduced IIS by daf-2 RNAi. B. RJ/eRJ supplementation 
cannot further delay the progression of paralysis in CL2006 worms with reduced IIS by age-1 RNAi. C. Reducing DAF-16 by daf-16 RNAi 
significantly abolished the beneficial effects of RJ/eRJ delaying the progression of body paralysis in AD worms. Each paralysis assay was 
repeated at least three independent times with similar results. “% paralysis” indicates the average paralysis among the multi-replicates and 
error bars represent the standard deviation. D.The transcript levels of aip-1, F10D7.5, mtl-1, sod-3, Y71H2AR.2, ZK218.8, hsp-16.2, hsp-
12.6, and T05G5.10 were measured using qRT-PCR in CL2006 worms supplemented with RJ/eRJ (2mg/ml and 1mg/ml, respectively). 
The data from three independent experiments were pooled to calculate the mean RNA level normalized to the internal control act-1. The 
standard errors of the mean (SEM) are shown. *, p < 0.05 when compared to non-treated controls.
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DISCUSSION
It has emerged that some anti-aging nutraceuticals 
could delay the development of neurodegenerative 
disorders. For instance, cranberry protected C. elegans 
from thermal stress and slowed down the development 
of AD [16, 50]. Antioxidant resveratrol not only had 
prolongevity effect but also delayed the development of 
Alzheimer’s disease and Parkinson’s disease [51, 52]. Our 
previous studies reported that RJ/eRJ supplementation 
not only extended C. elegans lifespan, but also increased 
their stress resistant capacity. This implied that RJ/eRJ 
consumption could lead to healthy aging in multicellular 
organisms. Hence, our present studies attempted to 
further investigate the potential beneficial effect of RJ/
eRJ on AD treatment and its underlying molecular 
mechanisms. Strikingly, our results showed that RJ/eRJ 
supplementation delayed the progression of paralysis in 
AD worms. Further genetic analyses suggested that RJ/
eRJ requires daf-16, rather than skn-1 and hsf-1, to protect 
against Aβ toxicity. Mechanistic studies demonstrated that 
RJ/eRJ modulates the transactivities of DAF-16 through 
IIS cascade. Moreover, RJ/eRJ consumption resulted in 
the reduction of Aβ species in AD worms and greatly 
increased the solubility of proteins in aged worms [45, 48, 
49]. Intriguingly, the improvement of protein solubility 
conferred by RJ/eRJ supplementation also required the 
function of DAF-16. Considering the correlation of protein 
solubility and proteostasis, and the imperative role of 
DAF-16 in regulating proteostasis, our findings suggested 
that RJ/eRJ may alleviate Aβ toxicity by promoting the 
function of proteostasis machinery in C. elegans through 
IIS and DAF-16. 
It was reported that reduction of the IIS pathway 
prevents neurodegeneration in worms and mammals, 
and this preventive effect relies on the transactivities of 
three important transcription factors (daf-16, skn-1, and 
hsf-1) [42]. Given that IIS played an essential role in RJ/
eRJ-mediated protection against Aβ toxicity (Figure 3), 
we thus wondered whether RJ/eRJ may preferentially 
influence the function of these downstream transcription 
factors contributing to the reduction of proteotoxicity. To 
address this concern, RNA interference was utilized to 
respectively knock down the gene expression of daf-16, 
hsf-1, and skn-1, respectively. Our genetic epistasis results 
showed that RNAi of either skn-1 or hsf-1 did not abolish 
RJ/eRJ-mediated progression delay of body paralysis 
(Figure 4A and 4B), while RNAi of daf-16 in CL2006 
AD worms completely abolished the progression delay of 
paralysis, relative to controls (Figure 3D). These findings 
indicated that RJ/eRJ’s protection against Aβ toxicity 
in C. elegans is mainly dependent on DAF-16. Given 
that inefficiency of proteostasis machinery results in the 
accumulation of aggregates [43], such as Aβ aggregates, 
we reasoned that RJ/eRJ supplementation protected AD 
worms against Aβ toxicity by improving the regulation of 
proteostasis. Considering that DAF-16 plays a pivotal role 
in proteostasis network [28], our results suggested that RJ/
eRJ supplementation selectively modulate the transactivity 
of DAF-16 to improve proteostasis in AD worms. 
Ben-Zvi et al. demonstrated that collapse of 
proteostasis leads to impaired protein solubility and 
increased cytotoxicity [48]. Reis-Rodrigues and colleagues 
further claimed that accumulation of insoluble proteins 
with diverse biological functions may be a general 
feature of normal aging and late-onset neurodegenerative 
Figure 4: skn-1 and hsf-1 are dispensable in RJ/eRJ-mediated protection against Aβ toxicity. A. RJ/eRJ supplementation 
can still delay the progression of Aβ toxicity-induced paralysis in AD worms with SKN-1level reduced by skn-1 RNAi. B. RJ/eRJ 
supplementation can still delay the progression of body paralysis in AD worms with HSF-1 level reduced by hsf-1 RNAi. Each paralysis 
assay was repeated at least three independent times with similar results. “% paralysis” indicates the average paralysis among the multi-
replicates and error bars represent the standard deviation.
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Figure 5: RJ/eRJ improves proteostasis in aged C. elegans in a DAF-16 dependent manner. A. RJ/eRJ treatment increases 
protein solubility in 10-day old N2 worms. B. RJ/eRJ supplementation increases protein solubility in 10-day old CL2006 AD worms. C. 
RJ/eRJ treatment cannot increase protein solubility in 10-day old daf-16 (mgDf50) mutant worms. Soluble proteins on the SDS-PAGE gel 
are quantified by using ImageJ software. Data are expressed as mean intensity from three independent experiments. The standard errors of 
the mean (SEM) are shown. p value was calculated using Student’s t-test. *, p < 0.05 when compared to controls.
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diseases [49]. Collectively, previous findings highlighted 
that a healthy proteostasis is associated with good protein 
solubility and attenuated proteotoxicity. Interestingly, 
our results showed that RJ/eRJ significantly increased 
protein solubility in both aged wild type worms and 
aged AD worms, which suggested that RJ/eRJ possessed 
the capability to help maintain a healthy proteostasis 
in C. elegans. Given that RJ/eRJ requires DAF-16 
to protect against Aβ toxicity, we speculated that 
DAF-16 is also essential in RJ/eRJ-mediated healthy 
proteostasis maintenance. In support of our speculation, 
our further protein solubility assay showed that RJ/eRJ 
supplementation barely altered the protein solubility in 
aged daf-16 deletion mutants. Taken together, our results 
attributed RJ/eRJ-mediated reduction of Aβ toxicity to 
DAF-16 and the improved proteostasis.
Given that most of, if not all, cellular functions 
depend on gene expression, the dependence of DAF-16 
in RJ/eRJ-mediated proteostasis improvement proposed 
that RJ/eRJ may modulate the target gene expression of 
DAF-16 to influence proteostasis network. To address this, 
we selected several DAF-16 target genes and performed 
qRT-PCR to measure their expression in AD worms 
treated with or without RJ/eRJ. Intriguingly, RJ/eRJ 
supplementation increased the expression levels of sod-3, 
mtl-1, hsp-12.6, hsp-16.2, and Y71H2AR.2 (Figure 3D). 
sod-3 and mtl-1 gene products play an important role in 
detoxification and homeostasis of ROS and heavy metal, 
respectively [53, 54]. hsp-12.6 and hsp-16.2 encode two 
essential chaperone proteins to prevent the aggregation of 
misfolded and unfolded proteins in response to proteotoxic 
stressors [55, 56]. Impressively, overexpression of HSP-
16.2 could suppress the Aβ toxicity in AD worms. 
Y71H2AR.2 encodes a protease, which may facilitate 
protein degradation through proteolysis [57]. Considering 
that stress response, molecular chaperone, and regulation 
of protein degradation are major components of the 
proteostasis network [11], our results implicated that RJ/
eRJ may alleviate Aβ toxicity by modulating proteostasis 
network through DFA-16. It is also worth noticing that 
expression of other selected genes, such as ZK218.8, 
T05G5.10, aip-1, and F10D7.5, was barely influenced 
by RJ/eRJ supplementation (Figure 3D), although they 
are probably related to proteostasis network. ZK218.8 
and T05G5.10 encode translation initiation factors and 
function in protein synthesis [57, 58], while aip-1 and 
F10D7.5 gene products function to facilitate toxic protein 
degradation under stress [59]. It was reported that RJ/
eRJ-mediated prolongevity relied on fine-tune of DAF-16 
transactivity through interplay with multiple proteins [18]. 
The expression preference of DAF-16 targets conferred 
by RJ/eRJ in AD worms actually suggested that RJ/eRJ 
may also fine-tune the transactivity of DAF-16, and in 
turn specifically up-regulate the expression of certain 
proteins associated with proteostasis network. It will be of 
great interest to decipher the RJ/eRJ-mediated fine-tune 
regulation on DAF-16 in AD worms. Of course, more 
experiments are needed to this end. 
A growing body of evidence suggests that bioactive 
substances in natural foods interplay with cellular proteins, 
nuclear acids, and lipids by the chemical modification or 
physical interaction, to influence human health [60]. It 
is conceivable that the bioactive ingredients in RJ may 
function through the similar modes of action to ameliorate 
Aβ toxicity in animals. Given that RJ is a unique mixture 
rich of proteins, carbohydrates, lipids, minerals, and 
vitamins [61], in order to boost the therapeutic effects of 
RJ, it is critical to determine its functional components 
corresponding to the reduction of proteotoxicity in cells. 
Indeed, our finding that RJ/eRJ depends on DAF-16 to 
improve the function of proteostasis provides a simple and 
clear readout to determine these active components from 
RJ/eRJ. 
Overall, our finding revealed the molecular 
mechanisms of RJ/eRJ-mediated alleviation of Aβ toxicity 
in C. elegans, and explicitly underscored the correlation 
of proteostasis maintenance and proteotoxicity reduction 
in cells. As both IIS/DAF-16(FOXOs) and proteostasis 
network are highly conserved in species ranging from C. 
elegans to human, the potential function of RJ/eRJ in AD 
treatment might also be beneficial to humans. 
MATERIALS AND METHODS
Strains and growth conditions
All strains were maintained at 16 °C on nematode 
growth medium (NGM) seeded with Escherichia coli 
OP50 feeding strain. Strains used in this study were as 
follows: N2 Bristol (wild type), CL2006 (AD worm), and 
daf-16 (mgDf50). All the strains were obtained from the 
Caenorhabditis Genetics Center (CGC), University of 
Minnesota.
Preparation of RJ and eRJ
The powder of RJ and eRJ were provided by 
Yamada Apiculture Center, Inc., Okayama, Japan. To 
prepare RJ and eRJ supplemented food, appropriate 
amount of RJ or eRJ in powder form were dissolved in 
sterile distilled water and suspended into the liquid NGM 
(2mg/mL RJ and 1mg/mL eRJ) one day before the assay 
[18].
RNA interference
RNA interference (RNAi) clones were grown 
overnight at 37°C on Luria Broth plate in the presence 
of tetracycline (12.5 µg/ml) and carbenicillin (25 µg/
Oncotarget54190www.impactjournals.com/oncotarget
ml). Bacterial colonies were inoculated and grown for 
8-12 hours, then induced with 2mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) for 4 hours at 37°C. Ten-
fold concentrated RNAi bacteria were seeded onto RNAi 
plates containing 25 µg/ml carbenicillin. The RNAi 
constructs targeting daf-2, age-1, daf-16, hsf-1, and skn-
1 were obtained from the C. elegans ORFeome RNAi 
library v1.1.
Worm paralysis assays
The assays using strain CL2006 were carried out 
as described by Cohen and colleagues [28]. Synchronous 
populations of CL2006 worms were prepared on NGM 
plates by allowing 10-15 hermaphrodites lay eggs 
overnight at 16°C, and the parents were removed the 
next day. The eggs were allowed to hatch, and 30 L4/
young adult worms per plate were used for each assay at 
20°C. All paralysis plots were done in triplicates, and a 
minimum of three independent trials were performed per 
condition. Nematodes were scored as paralyzed if they 
exhibited “halos” of cleared bacteria around their heads 
(indicative of insufficient body movement to access food) 
or failed to undergo full body wave propagation upon 
the nose prodding. Worms were checked every day until 
all worms were paralyzed. The data were pooled, and 
the percentage of paralyzed worms was calculated and 
analyzed using Student’s t-test. p < 0.05 was accepted as 
statistically significant.
Western blotting of Aβ species
Rabbit polyclonal Aβ1-42 primary antibodies were 
from Abcam (ab39377). For Western blot analysis, 
CL2006 worms were synchronized by allowing 10-15 
hermaphrodites to lay eggs overnight on OP50 seeded 
NGM plates at 16°C. The parents were removed, and 
eggs were allowed to hatch and develop to the L4 stage. 
Subsequently, worms were transferred to RJ (2mg/mL) / 
eRJ (1mg/mL) containing NGM plates and continued to 
grow at 20°C. CL2006 worms on regular NGM plates 
without RJ/eRJ served as control. After 10 days of growth, 
worms were transferred to micro-centrifuge tubes and 
washed with S-basal followed by protein immobilization 
on polyvinylidenefluoride (Bio-Rad) membrane. 
Polyvinylidenefluoride membrane was incubated with 
primary antibodies (1:1,000) diluted in 5% nonfat dry 
milk and then with secondary, HRP-conjugated goat anti-
rabbit antibodies (Genscript, A00098; diluted 1:10,000). 
ACTIN was used as loading control, and the anti-ACTIN 
antibodies (MAB1501) were from EMD Millipore. 
Detection was undertaken with standard ECL protocol. 
Mean intensity of Aβ signals was analyzed using ImageJ 
software (National Institute of Health).
Soluble protein extraction
The soluble protein extraction was performed 
as described previously with alterations [17, 49]. 
Synchronous populations of eggs were prepared by 
alkaline hypochlorite treatment of gravid adults grown 
at 16°C. Eggs were allowed to hatch and develop by 
transferring to OP50-seeded NGM plates containing 
RJ (2mg/mL) or eRJ (1mg/mL) at 20°C. Eggs hatched 
and developed on OP50-seeded NGM plates without 
RJ/eRJ served as controls. Both worms treated with or 
without RJ/eRJ were collected 10 days after L4 stage. 
Three separate replicates of each sample (about 200mg 
[wet weight] of worms) were collected. Total protein 
extracts were produced in phosphate-buffered saline by 
sonication on ice, and then the total protein concentration 
was determined by conducting a bicinchoninic acid assay. 
Next, the normalized protein samples were spun for 10 
minutes at 14,000g to remove the insoluble fraction. The 
same volume of supernatants (soluble fraction) was loaded 
and analyzed by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis. Mean intensities of protein bands 
were analyzed using ImageJ software (National Institute 
of Health).
Gene expression analysis by quantitative real-time 
PCR
CL2006 worms were synchronized by allowing 
10-15 hermaphrodites to lay eggs for 6 hours on OP50 
seeded NGM plates at 16°C. The eggs were allowed to 
hatch and develop. The L4 /young adult worms were 
transferred to RJ/eRJ (2 and 1mg/mL respectively) NGM 
plates (containing 50 µg/mL FUDR to prevent the growth 
of progeny) to maintain for 6 days. CL2006 worms on 
regular NGM (containing FUDR) plates without RJ/eRJ 
served as controls. Worms at the 6-day old stage were 
collected with M9 buffer into a 50-100-µl pellet. RNA 
was prepared using RNAzol® RT reagent (Molecular 
Research Center) and stored at −80°C. Complementary 
DNA was prepared by using Invitrogen SuperscriptTM 
first-strand synthesis system for RT-PCR (Invitrogen). 
Real-time PCR was performed using using SsoFastTM 
EvaGreen® Supermix (Bio-Rad) and the CFX96TM real-
time PCR detection system according to the manufacturer 
suggested protocol (Bio-Rad). The quantitative real-time 
PCR (qRT-PCR) conditions were as follows: 95°C for 3 
minutes, followed by 40 cycles of 10 seconds at 95°C, 
and 30 seconds at 60°C. act-1 was used as an internal 
control to normalize the expression level of target 
transcripts. Relative fold-changes for transcripts were 
calculated using the comparative CT(2
−ΔΔCT) method (43). 
Each qRT-PCR experiment was repeated three times 
using independent RNA/cDNA preparations. The data 
were pooled and analyzed using student’s t-test, and a 
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p value < 0.05 was accepted as statistically significant. 
The qRT-PCR primers for hsp-12.6 are as follows: 
5′-ATGATGAGCGTTCCAGTGATGGCTGACG-3′ 
(F) and5′-TTAATGCATTTTTCTTGCTTCAATG
TGAAGAATTCC-3′ (R). Primers for hsp-16.2 are 
as follows: 5′-TTGCCATCAATCT CAACGTC-3′ 
(F) and 5′-CTTTCTTTGGCGCTTCAATC-3′ 
(R). Primers for sod-3 are as follows: 
5′-CCAACCAGCGCTG-AAATT CAATGG-3′ (F) 
and 5′-GGAACCGAAGTCGCGCTTAATAGT-3′ 
(R). Primers for mtl-1 are as follows: 
5′-ATGGCTTGCAAGTGTGACTG-3′ (F) and 
5′-CACATTTGTCTCCGCACTTG-3′ (R). Primers for aip-
1 are as follows: 5’- GAGCGGGATCACAGTTGTGAG-3’ 
(F) and 5’- GATGTGATTGAATCCGTCCAG-3’ 
(R). Primers for F10D7.5 are as follows: 5’- 
GCACTAGAGGACCATTACAGTT-3’ (F) 
and 5’- CGTTCTCGTCAATCTCGATAGG-3’ 
(R). Primers for ZK218.8 are as follows: 5’- 
TGCTACTGGCTGTGTGTTAG-3’ (F) and 
5’- CAATAGTTCCGGCATTCACATAAT-3’ 
(R). Primers for T05G5.10 are as follows: 5’- 
GGAGACTTGGGAAACACTATCC-3’ (F) 
and 5’- TGTATCCGAGAATAGCCTCCT-3’ 
(R). Primers for Y71H2AR.2 are as follows: 
5’- GAGTTGTGGCAGAGGGTAATG-3’ (F) 
and 5’- GGATGGGTTGTAGATTCCGATTT-3’ 
(R). Primers for act-1are as follows: 5′- 
CCAGGAATTGCTGATCGTATGCAGAA-3′ (F) and 
5′-TGGAGAGGGAAGCGAGGATAGA-3′ (R).
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